Tempus and JW Pharmaceutical Collaborate to Advance Early R&D with Real-World Data
Tuesday, October 29, 2024
Tempus has formed a collaboration with JW Pharmaceutical to advance early-stage cancer research.
This partnership aims to harness both real-world data (RWD) and biological modelling to support faster hypothesis generation and validation, streamlining early therapeutic research in oncology.
JW Pharmaceutical, a frontrunner in integrating RWD into drug development, is now leveraging Tempus' diverse multimodal dataset and extensive library of organoid models to enhance research across multiple cancer indications.
Through this collaboration, JW Pharmaceutical's research teams are utilising Tempus' biological modelling platform, which includes a wide range of patient-derived organoid models.
These models reflect unique patient tumours and are linked to Tempus’ real-world, multimodal dataset via its next-generation sequencing assay, xT.
This integrated approach enables insights from organoid screenings to be applied to real-world patient populations, potentially offering a deeper understanding of treatment outcomes.
By embracing these advanced methods, JW Pharmaceutical aims to identify biomarkers, screen pipeline assets, and guide prioritisation decisions, ultimately accelerating the path towards targeted cancer therapies.
This strategic collaboration not only reflects JW Pharmaceutical’s commitment to data-driven drug development but also aligns with broader global trends in precision oncology.
Source: businesswire.com
